Non-small cell lung cancer · line 2 · Amivantamab monotherapy (CHRYSALIS) — 2L EGFR Exon 20 insertion NSCLC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-AMIVANTAMAB-MONO-NSCLC-EX20INS |
| ID | IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-CHRYSALIS-PARK-2021 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L for EGFR Ex20ins post-platinum. PAPILLON 1L combo (ami+carbo+pem) is separate future Indication. Mobocertinib withdrawn 2023; zipalertinib / furmonertinib in development.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Indication
IND-NSCLC-EGFR-1L-AMI-LAZ- IND-NSCLC-EGFR-1L-AMI-LAZ